JPMorgan raised the firm’s price target on BeiGene to $200 from $194 and keeps an Overweight rating on the shares. The firm updated estimates following BeiGene’s “strong” Q2 Brukinsa results. Given strong Brukinsa growth, JPMorgan sees BeiGene well on its way to profitability, which it estimates could take place as soon as next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: